<DOC>
	<DOC>NCT00002100</DOC>
	<brief_summary>To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.</brief_summary>
	<brief_title>Phase I/II Study of Curdlan Sulfate</brief_title>
	<detailed_description>In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested. In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Curdlan sulfate</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV seropositivity. No current AIDSdefining opportunistic infection, lymphoma, Kaposi's sarcoma, or other malignancy. CD4 count &lt; 500 cells/mm3. No critical illness that would shorten life expectancy to &lt; 16 weeks. Exclusion Criteria Concurrent Medication: Excluded: Antiretroviral or other experimental therapies. Anticoagulants. Steroids. Cytotoxic or immunosuppressive agents. Concurrent Treatment: Excluded: Radiotherapy. Patients with the following prior condition are excluded: History of heparin sensitivity. Prior Medication: Excluded within 1 month prior to study entry: Antiretroviral or other experimental therapies. Anticoagulants. Steroids. Cytotoxic or immunosuppressive agents. Prior Treatment: Excluded: Radiotherapy within 1 month prior to study entry. Active IV drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 1994</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>curdlan sulfate</keyword>
</DOC>